Dextech Medical AB (XSAT:DEX)
9.98
+0.28 (2.89%)
At close: Sep 14, 2026
Dextech Medical AB Revenue
In the fiscal year ending June 30, 2026, Dextech Medical AB had annual revenue of 5.01M SEK with 55.38% growth. Dextech Medical AB had revenue of 1.45M in the quarter ending June 30, 2026, with 145.33% growth.
Revenue
5.01M
Revenue Growth
+55.38%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
184.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 5.01M | 1.78M | 55.38% |
| Jun 30, 2025 | 3.22M | -2.16M | -40.15% |
| Jun 30, 2024 | 5.39M | -3.33M | -38.18% |
| Jun 30, 2023 | 8.71M | 5.60M | 179.60% |
| Jun 30, 2022 | 3.12M | 2.48M | 390.65% |
| Jun 30, 2021 | 634.98K | 38.64K | 6.48% |
| Jun 30, 2020 | 596.34K | -1.67M | -73.66% |
| Jun 30, 2019 | 2.26M | -6.27M | -73.47% |
| Jun 30, 2018 | 8.53M | -69.24K | -0.80% |
| Jun 30, 2017 | 8.60M | 57.00K | 0.67% |
| Jun 30, 2016 | 8.55M | 935.75K | 12.30% |
| Jun 30, 2015 | 7.61M | 1.79M | 30.79% |
| Jun 30, 2014 | 5.82M | 2.14M | 57.98% |
| Jun 30, 2013 | 3.68M | 736.97K | 25.02% |
| Jun 30, 2012 | 2.95M | -1.40M | -32.16% |
| Jun 30, 2011 | 4.34M | 2.81M | 184.25% |
| Jun 30, 2010 | 1.53M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sustainion Group AB | 694.18M |
| Bergholm Holding AB | 575.56M |
| Angler Gaming | 359.87M |
| Gullberg & Jansson AB | 288.92M |
| SolidX AB | 126.85M |
| Krona Public Real Estate AB | 88.22M |
| BPC Instruments AB | 63.97M |
| PEPTONIC medical AB | 10.39M |
Dextech Medical AB News
- 16 days ago - Dextech Medical AB Quarterly report: Q4 2026 - Filings
- 4 months ago - Dextech Medical AB Quarterly report: Q3 2026 - Filings
- 6 months ago - Dextech Medical AB Quarterly report: Q2 2026 - Filings
- 10 months ago - Dextech Medical AB Quarterly report: Q1 2026 - Filings